AstraZeneca’s Imfinzi in combination with chemotherapy has been approved in the U.S. for the treatment of adult patients with resectable early-stage non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements. In this regimen, patients are treated with Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Healthcare Stocks Rise despite Medicare Price Cuts for Their Drugs
- U.S. to announce prices for drugs in Medicare negotiations, NY Times says
- Genprex provides clinical study updates for its Acclaim 1 and 3 trials
- AstraZeneca’s Imfinzi and Lynparza approved in EU in endometrial cancer patients
- Texas probes CenterPoint, Carlyle weighs Nobian sale: Monday Buzz